UNICREDIT BANK/CALL/EVOTEC/18/1/18.09.24 Stock

Warrant

DE000HC9YT55

Real-time BOERSE MUENCHEN 05:45:12 2024-07-16 am EDT
0.001 EUR 0.00% Intraday chart for UNICREDIT BANK/CALL/EVOTEC/18/1/18.09.24
6 months-99.95%
Current year-99.98%
Date Price Change
24-07-16 0.001 0.00%
24-07-15 0.001 0.00%
24-07-12 0.001 0.00%
24-07-11 0.001 0.00%
24-07-10 0.001 0.00%

Real-time BOERSE MUENCHEN

Last update July 16, 2024 at 05:45 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer UniCredit UniCredit
WKN HC9YT5
ISINDE000HC9YT55
Date issued 2023-10-17
Strike 18
Maturity 2024-09-18 (65 Days)
Parity 1 : 1
Emission price 2.75
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.5
Lowest since issue 0.001

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
8.87 EUR
Average target price
20.72 EUR
Spread / Average Target
+133.58%
Consensus